Skip to main content

Table 3 Adverse events

From: Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study

  Events Incidence rate (per 100 days)
Anakinra 100 mg/day (194 total days)
Serious events
  Hospitalized to rule out thrombus 1 0.5
Non-serious events
  Injection site reaction 3 1.5
  Oral thrush 1 0.5
  Other 2 1.0
Anakinra 200 mg/day (1371 total days)
Serious events
  Pulmonary artery hypertension 1 0.1
  Pre-syncope 1 0.1
  Non-cardiac chest pain 1 0.1
Non-serious events
  Upper respiratory infection 5 0.4
  Alopecia 2 0.2
  Edema 2 0.2
  Vaginal yeast infection 1 0.1
  Other 9 0.7
Anakinra 300 mg/day (322 total days)
Serious events
  • None 0 0
Non-serious events
  • Upper respiratory infection 2 0.6
  • Vaginal yeast infection 1 0.3
  • Other 2 0.6